Genmab — Oktober 2020

[E_L]

Sarclisa was approved in March in the U.S. for the treatment of adults with relapsed refractory multiple myeloma (RRMM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and in June by the European Commission in certain adults with RRMM. Third-quarter Sarclisa sales were €13 million of which €9 million was generated in the U.S. despite the challenging launch environment due to COVID-19. Sarclisa is now launched in the U.S., Austria, Japan,

[E_L]

Switzerland, Canada and UK. Five additional commercial launches are expected by year-end.

[E_L]

The development of the combination of Sarclisa and atezolizumab in squamous cell carcinoma of the head and neck has been terminated.

[E_L]

The multiple myeloma trial for SAR442257, an antiCD38 xCD28xCD3 trispecific antibody, dosed its first patient.

[deleted-user]

Thanks to @EL for pushing news feed today. The markets seems to appreciate the flow

[deleted-user]

@E L

[deleted-user]

Sr
y for the last 2 posts - originally regards to E L

[E_L]

yeah, EL is the stock ticker for Estée Lauder lol (which trades over 200 so don't know where the 75.8 comes from). The funny thing is that each time somebody types it like that here, it trades down, always - . I hope that is not a reflection on me

[Hamming]

Nyt fra Immatics https://investors.immatics.com/news-releases/news-release-details/immatics-presents-preclinical-proof-concept-data-tcr-bispecifics

[Hamming]

Spændende samarbejdspartner

[Plimsoller]

God morgen .-)

[Plimsoller]

[Helge_LarsenPI-redaktør]

God morgen.

[transalp]

Go morgen..

[E_L]

Seagen :

Presented Results from Tisotumab Vedotin (TV) Pivotal Trial at ESMO: In September 2020, Seagen and Genmab presented positive results at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 from the phase 2 single-arm clinical trial known as innovaTV 204. The trial is evaluating TV for the treatment of patients who have relapsed or progressed on or after prior treatment for recurrent or metastatic cervical cancer. The companies plan to submit a BLA to the FDA,

[E_L]

which could support accelerated approval in the U.S.

[E_L]

Seagen press release https://investor.seagen.com/press-releases/news-details/2020/Seagen-Reports-Third-Quarter-2020-Financial-Results/default.aspx
and presentation https://s21.q4cdn.com/327105422/files/doc_financials/2020/q3/Q3-Slides_FINAL-for-website.pdf

[E_L]

Seagen's (SGEN) CEO Clay Siegall on Q3 2020 Results - Earnings Call Transcript https://seekingalpha.com/article/4382954-seagens-sgen-ceo-clay-siegall-on-q3-2020-results-earnings-call-transcript?part=single

[E_L]

"we and Genmab recently amended specifics of the TV global commercialization plan, whereby Seagen will lead global commercial activities, except in Japan. We will continue joint decision-making on worldwide strategy and Seagen and Genmab will co-promote TV in the U.S. In addition, Seagen will lead the majority of global operational development activities.

[E_L]

We and Genmab plan to submit the BLA to the FDA to support accelerated approval in this indication and to initiate a randomized confirmative trial of TV and cervical cancer in the coming months. We are also advancing clinical trials of TV monotherapy in other cancers and in combination with other agents.